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Large-scale cancer genomics projects are just starting to trickle into the literature, and the flow
will only grow in size and impact in the upcoming year. Nevertheless, the studies so far are already
reshaping our view of tumor progression, especially in terms of how cancer manipulates the
epigenome for fast growth and adaptability. This Select discusses recent genomics articles that,
collectively, offer a new mechanism for cancer evolution and highlight the rising importance of
chromatin remodeling factors in cancer.A multidimensional scaling of methylation for
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Cancer cells have remarkable plasticity. They quickly respond to changes in their
environment by switching phenotypes and even back-tracking out of differenti-
ated states. Now, a landmark study by Hansen et al. (2011) uncovers a new
mechanism driving cancer cells’ adaptability: increased stochasticity in DNA
methylation levels across the genome.
Methylating cytosines in promoters generally silences genes, andwhen a cyto-
sine is immediately next to a guanine (i.e., ‘‘CpG’’ dinucleotide), the cytosine is
often methylated. Thus, studies on DNA methylation in cancer have focused
primarily on gene promoters and genomic regions with a high concentration of
CpG dinucleotides. Now, Hansen et al. decide to take a broader approach and
examine regions with lower CpG density. Using a custom-made Illumina micro-
array, the authors measure methylation levels at 384 sites in 290 tumor and
normal samples, including colon, lung, thyroid, breast, and Wilms’ tumors.
Compared to normal tissues, all five cancers display significant increases in
methylation variability at 70%–92% of CpG sites—that is, the standard devia-
tions for methylation levels are strikingly higher in cancer than in normal tissue.
The authors then use bisulfate sequencing on three matched colorectal tumorsto characterize themethylation pattern on a genomic scale. This analysis reveals large blocks of hypomethylated DNA, which include
genes associatedwith tumor heterogeneity and progression. Although80%of the genes in these blocks are silenced in both cancer
and normal samples, the variability in gene expression across samples is substantially higher in cancer than in normal tissue, as the
authors observed for methylation levels.
Together, these findings suggest a provocative new model for how cancer cells can adapt so quickly to fluctuating environments:
increased randomness inmethylation levels enhances the variability of gene expression across a uniform population of cells, allowing
selective pressures to select for epigenetic configurations most suitable for a given condition. In other words, the epigenetic insta-
bility provides the opportunity for Darwin-like evolution to occur at the cellular level.
Hansen, K.D., et al. (2011) Nat. Genet. 43, 768–775.Genome-wide visualization of somatic
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If epigenetic patterns, such as DNA and histone modifications, contribute to cancer’s
evolution and tumorigenesis, then proteins involved in shaping the chromatin land-
scape should be key drivers in a broad range of cancers. Now, four independent exome
sequencing studies identify multiple chromatin remodeling factors as tumor suppres-
sors and oncogenes in non-Hodgkin lymphoma (Morin et al., 2011; Pasqualucci
et al., 2011).
Until now, only a few genetic drivers have been identified for the most common forms
of non-Hodgkins lymphoma—diffuse large B cell lymphoma (DLBCL) and follicular
lymphoma. To hunt for more tumor suppressors in lymphoma, Morin et al. (2011)
sequence the genomes or exomes of 15 lymphoma cases (14 DLBCLs and 1 follicular
lymphoma) and then perform RNA sequencing on these cases plus 113 more samples.
Independently, Pasqualucci et al. combine exome sequencing and copy number
analysis on six DLBCL cases. Both groups identify 100 genes recurrently mutated in
multiple tumors, and both pools of genes are enriched with enzymes involved in DNA
methylation and histone modifications, such as histone methyltransferases and
acetyltransferases. In both studies, 10% of the lymphomas carry mutations in the
MEF2B gene, which encodes a factor involved with histone acetylation. More impor-
tantly, Morin et al. find that 89% of the follicular lymphoma cases carry mutations in
theMLL2 gene, and both groups observeMLL2 mutations in 24%–32% of the DLBCLCell 147, September 30, 2011 ª2011 Elsevier Inc. 5
tumors, makingMLL2 the most common mutated gene in non-Hodgkin lymphoma. MLL2 encodes an H3K4-specific histone meth-
yltransferase involved in gene activation. The mutation patterns of MLL2—that is, a high percentage of inactivating mutations—
strongly indicate thatMLL2 is a critical tumor suppressor in non-Hodgkin lymphoma. Moreover, bothMLL2 andMEF2B display signs
that selective pressures accelerated the acquisition of nonsynonymous point mutations, providing further evidence that these chro-
matin remodelers are core drivers of non-Hodkgin lymphoma.
Morin, R.D., et al. (2011) Nature 476, 298–303.
Pasqualucci, L., et al. (2011) Nat. Genet. 43, 830–837.Histology image of a hepatitis C-associ-
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Using a similar strategy as the two studies above on lymphoma, Gui et al. (2011) and Li et al.
(2011) also identify chromatin remodelers as new tumor suppressors in bladder carcinoma
and hepatitis C-associated liver cancers (HCC), respectively. In both studies, the authors
start by sequencing the exomes for 10 different tumors (to 90-fold coverage); identify
genes with nonsilent mutations in more than one tumor; and then sequence these genes
in 100 more samples. For bladder cancer, 8 of the 49 most frequently mutated genes
encode chromatin remodeler proteins, including a SWI/SNF-related gene (ARID1A),
a histone demethylase (UTX), acetyltransferases (CREBBP and EP300), and methyltrans-
ferases (MLL andMLL3). For HCC,18.2%of the samples harbor inactivatingmutations in
the ARID2 gene, which encodes a subunit of the chromatin remodeling complex PBAF
(polybromo and BRG1-associated factor). In both studies, the mutational patterns
observed for these seven chromatin remodelers strongly implicate these genes as tumor
suppressors in bladder cancer or HCC.
A major strength of the study by Hansen et al. (see first summary) is that the increasedvariability in methylation and gene expression was observed across diverse types of cancers, suggesting that this epigenetic insta-
bility is a general property of cancer. Now, a related trend seems to be arising from exome sequencing projects: disrupting enzymes
that maintain the proper epigenetic landscape drives malignant transformation in diverse types of cancers, from non-Hodgkin
lymphoma to bladder and liver cancers. Collectively, these studies also suggest that targeting chromatin remodeler genes may
be a particularly productive approach for finding new tumor suppressors and oncogenes in future sequencing projects.
Gui, Y. et al. (2011). Nat. Genet. 43, 875–878.
Li, M., et al. (2011). Nat. Genet. 43, 828–829.The confocal image in the Sputnik satel-
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Mutations in the breast cancer susceptibility gene 1 (BRCA1) increase the risk for developing
breast and ovarian cancers up to 95%, and it is generally accepted that BRCA1 stops
tumorigenesis by promoting the repair of DNA breaks through homologous recombination.
Now, Zhu et al. (2011) challenge this classic view by presenting evidence that BRCA1 main-
tains genomic stability through the ubiquitination of histone H2A in heterochromatin.
Centromeres are surroundedby heterochromatin, which contains large arrays of repeating
sequences called satellite DNA. These repeats are thought to be noncoding and largely
silenced by heterochromatin formation. The BRCA1 protein contains a domain with ubiquitin
E3 ligase activity, and previous studies have shown that, in vitro, BRCA1 preferentially ubiq-
uitinatesH2A, a histone variant implicated in gene silencing. Now, Zhu et al. demonstrate that
deleting BRCA1 disrupts the organization of heterochromatin, decreases levels of ubiquiti-
nated H2A histones at heterochromatin, and increases the expression of transcripts from
the satellite DNA. Next, the authors show that boosting transcription of the satellite DNA
surprisingly causes many abnormalities seen in BRCA1-deficient cells, such as deficiencies
in homologous recombination and impaired chromosomal segregation. Then, when the
authors overexpress an H2A-ubiquitin fusion protein, the satellite DNA is resilenced and
many of theBRCA1-linkeddefects improve, including p53-inducedapoptosis, growth arrest,
and impaired homologous recombination. Zhu and colleagues find that these satellite tran-
scripts are also increased in breast cancer tumors from both humans and mice harboring
BRCA1 mutations. Together, these findings suggest that BRCA1 exerts its tumor-suppres-
sive effects by maintaining the integrity of heterochromatin. Although many questions still
remain, such as how the satellite transcripts alter DNA stability and integrate with BRCA1’s
known role at DNA breaks, the study may have unlocked an entirely new route for tumor
evolution and adaptability. It also reminds us that, clearly, we are just beginning to become
privy to the dangerous cabal that cancer has with chromatin and the epigenome.
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